



**NDA 204768 • TIVORBEX<sup>®</sup> (indomethacin) CAPSULES • SEQUENCE NUMBER 0119 •  
RESPONSE TO PREA NON-COMPLIANCE LETTER**

July 10, 2018

Sharon Hertz, MD, Director  
Division of Anesthesia, Analgesia, & Addiction Products  
Center for Drug Evaluation and Research  
Food and Drug Administration  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

**Re: NDA 204768 for Tivorbex<sup>®</sup> (indomethacin) Capsules  
Response to PREA non-compliance letter**

Dear Dr. Hertz:

Under the provisions of section 505B(d)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)[21 U.S.C. 355c(d)(1)], Iroko is responding to your [PREA NON-COMPLIANCE LETTER](#) dated June 19, 2018.

Postmarketing Requirement (PMR) Study 2128-2 remained scheduled for June 1, 2018 after a request for deferral ([Sequence 0112 submitted March 8, 2018](#)) was denied.

The June 1, 2018 date was missed due to issues with developing an acceptable pediatric formulation of Tivorbex. Iroko has had an ongoing dialog with the Division about this issue that has resulted in establishment of a Type C meeting on November 28, 2018.

This submission is provided entirely in eCTD (electronic Common Technical Document) format; therefore, no Table of Contents is being provided.

If you have any questions or require additional information regarding this submission, please do not hesitate to contact me, at 267.546.1428, or via email at [jmolt@iroko.com](mailto:jmolt@iroko.com).

Sincerely,

**J.T. Molt, Ph.D.**  
Digitally signed by J.T. Molt, Ph.D.  
DN: cn=J.T. Molt, Ph.D, o=Iroko Pharmaceuticals, LLC,  
ou=Interim Head Regulatory Affairs, email=jmolt@iroko.com,  
c=US  
Date: 2018.07.06 13:08:04 -0400

James T. Molt, Ph.D  
Interim Head Regulatory Affairs  
Iroko Pharmaceuticals, LLC  
One Kew Place, 150 Rouse Blvd.  
Philadelphia, PA 19112  
(O) 267.546.1428  
(F) 267.546.3004  
[jmolt@iroko.com](mailto:jmolt@iroko.com)



The total size of this electronic submission is approximately 3 MB

All files were checked and verified to be free of viruses prior to being sent via the Electronic Submission Gateway using McAfee Version 21.2, Build 21.2.125, scan engine 3400.0 and with a virus definition file version 7/9/2018.